Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody

Trial Profile

A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Melphalan flufenamide (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms HORIZON
  • Sponsors Oncopeptides
  • Most Recent Events

    • 01 Sep 2023 Results of longer follow-up analysis assessing prognostic subgroups impacting survival in updated data from two clinical trials OCEAN and HORIZON Studies published in the Clinical Lymphoma, Myeloma & Leukemia
    • 27 Oct 2022 This trial has been discontinued in Spain (Date of the global end of the trial : 11-Nov-2021), according to European Clinical Trials Database record.
    • 01 Sep 2022 Results assessing comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 study, belantamab mafodotin in DREAMM-2, selinexor plus dexamethasone in STORM Part 2 and melphalan flufenamide plus dexamethasone in HORIZON study published in the Clinical Lymphoma, Myeloma & Leukemia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top